Article

CXL cytotoxicity digs deep

Author(s):

Often forgotten in the buzz over corneal crosslinking (CXL) is that the procedure kills cells down to 300 µm deep, knocking out everything in its path, including microorganisms and keratocytes, said Theo Seiler, MD, PhD.

New Orleans-Often forgotten in the buzz over corneal crosslinking (CXL) is that the procedure kills cells down to 300 µm deep, knocking out everything in its path, including microorganisms and keratocytes, said Theo Seiler, MD, PhD.

"This is a powerful method of killing germs inside the cornea,” said Dr. Seller, professor of ophthalmology at the University of Zurich and chairman of IROC, Zurich. "The loss of cells is persistent-there is still a loss after 3 years.”

Dr. Seiler, who introduced CXL, said he sees tremendous applications for melting diseases.

"In these diseases, there is a constant thinning, a loss of tissue, but if you can delay that-or make the collagen more resistant-the equilibrium can shift between catalysis and synthesis to where there’s augmentation," he said.

Separate studies released this year in Iran and Europe continue to suggest that CXL is an effective procedure with long-term results, Dr. Seller said.    

Complication rates for these new studies ranged from 0% to 13%, with a failure rate of 2%. Other studies support these findings, as there is almost complete absence of adverse reactions to the treatment, he said.

During CXL, new chemical bonds are created between molecules, translating not only to well-documented stable bridges that reinforce the corneal structure, but also, as Dr. Seiler emphasized, making the collagen more resistant against digestive enzymes.

“It is not correct to call this procedure collagen crosslinking,” he said, “but corneal crosslinking, as the changes are not only in the skin collagen.”

 

For more articles in this issue of Ophthalmology Times Conference Brief click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.